APIs and Excipients

Colorcon Ventures Invests in AI Solutions Provider

August 13, 2020

Atomwise’s technology, AtomNet, works to eliminate the barriers of physical screening for small molecule drug discovery.

Allegations Put Kodak Pharmaceuticals Loan on Hold

August 10, 2020

Citing undisclosed allegations against Kodak, the DFC placed a hold on a potential $765 million loan to launch US-based API manufacturing.

Ensuring a Safe and Robust Supply of Pharma Materials

August 03, 2020

The COVID-19 pandemic has raised several questions about the safety of the pharmaceutical materials supply chain. Is onshoring the answer?

Key Ingredients Needed to Drive the Success of Continuous Manufacturing

August 03, 2020

Understanding and overcoming excipient variation are crucial for successful continuous processes.

Commercialization Poses Challenges for Cell and Gene Therapies

August 02, 2020

The early success seen on the market for approved cell and gene therapies poses both technical and manufacturing challenges for pipeline candidates on the road to commercialization.

CordenPharma Increases US Peptide Manufacturing Capacity

July 08, 2020

CordenPharma added a 3000-L solid-phase peptide synthesis vessel to its GMP API facility in Boulder, CO.

VAR2 Pharmaceuticals Wins MilliporeSigma’s Advance Biotech Grant

July 08, 2020

VAR2 Pharmaceuticals has been selected for its development of a drug-conjugated malaria protein that potentially selectively binds to most human tumor types.

BARDA, DOD Award $450-Million COVID-19 Manufacturing and Supply Contract to Regeneron

July 08, 2020

BARDA and DOD have awarded a $450-million contract to Regeneron Pharmaceuticals to manufacture and supply an investigational double antibody cocktail in development for treating COVID-19.

Intravacc, CimCure Partner to Develop COVID-19 Vaccine

July 02, 2020

Intravacc will license CimCure’s iBoost technology, and the companies will jointly develop a COVID-19 vaccine candidate.

Can RNA Simplify Gene Therapy Development?

July 02, 2020

RNA is easier to manipulate than DNA but challenging to deliver to the right cells.